Shares of 10x Genomics surged 10.3% to $57.39 on Monday, extending a post-earnings rally that has lifted the stock roughly 22% in three trading sessions. The catalyst: a wave of analyst price-target hikes following a Q2 earnings beat and raised full-year guidance — all anchored by red-hot demand for the company's new spatial biology instrument, Atera. For shareholders, the central question is whether a product still constrained by factory capacity can sustain a stock trading well above every fresh target on the Street.

• The Earnings Beat Was Real, but the Headline Numbers Mislead

The -$0.14 EPS loss beat consensus of -$0.23 by 38%, and $151 million in revenue topped the $146.9 million estimate by 2.8%. But context matters: total revenue fell from $172.9 million a year ago largely because one-time patent-settlement income dropped from $27.8 million to $1.9 million.

Strip out those settlements, and the core business grew about 3% — steady, not spectacular.

• Atera Orders Already Exceed This Year's Delivery Plan

Booked orders by the end of Q2 were "well above" the roughly 40 instruments 10x expects to ship in 2026, with production capacity — not demand — as the bottleneck.

Executives suggested consumable usage per Atera system could eventually reach twice that of its predecessor, Xenium, at full utilization — a significant revenue-per-box upgrade. However, analysts asked whether Atera could cannibalize existing products; management conceded "some moderation" but said Atera should more than offset it over time.

• Raised Guidance Nudges, Not Leaps

Full-year revenue guidance rose to $610 million–$630 million, implying 2%–5% organic growth.

That midpoint of $620 million is only slightly above the prior Street consensus of $613.7 million — a modest lift that depends on a Q4-heavy Atera ramp.

• The Stock Has Outrun Wall Street's Targets

Canaccord raised its target to $60, Piper Sandler to $47, Stifel to $50, and Morgan Stanley to $40. At $57.39, TXG already trades above all but one of those marks. The company remains unprofitable, still posting operating losses , and its margin improvement partly relied on $2.6 million in one-time tariff refunds . Investors are pricing in an Atera future that factory floors have not yet delivered.